Curis to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference.CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the Rodman rod·man n. One who carries and employs a leveling rod under the supervision of a surveyor. & Renshaw 5th Annual Global Healthcare Conference, which is being held on May 19-20, 2008 in Monte Carlo Monte Carlo (môNtā` kärlō`), town (1982 pop. 13,150), principality of Monaco, on the Mediterranean Sea and the French Riviera. , Monaco. Curis' presentation will take place on Monday, May 19th at 9:30 a.m. Eastern Daylight Time (3:30 p.m. local time). Daniel R. Passeri, MSc., J.D., Curis' President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will provide a presentation that includes an overview of the status of GDC-0449, which is an orally-administered small molecule inhibitor of the Hedgehog hedgehog, Old World insectivorous mammal of the family Erinaceidae, related to moles and shrews. The spiny hedgehogs are found in Africa and Eurasia, except SE Asia. They have rounded bodies up to 13 in. pathway that our collaborator Genentech that has just entered phase II clinical testing. Mr. Passeri will also discuss CUDC-101 and Curis' other targeted cancer programs in addition to other corporate activities. There will also be a corresponding webcast of the presentation, which can be accessed by visiting: http://www.wsw.com/webcast/rrshq13/cris The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will also be available for 30 days on the Investor Relations Investor relations The process by which the corporation communicates with its investors. section of the Curis website at www.curis.com. About Curis, Inc. Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its targeted cancer drug development platform, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion